Patent classifications
C07C61/40
Crystal of tefluthrin, preparation method therefor and use thereof
The present invention belongs to the technical field of fine chemicals and relates to a new crystalline form of tefluthrin, a preparation method therefor and the use thereof. The preparation method specifically comprises: taking an amorphous tefluthrin or a solid tefluthrin other than the tefluthrin as described in the present invention as a raw material, firstly preparing the raw material into an amorphous substance at room temperature, and then allowing the amorphous substance to cool to 5° C. to −24° C. to obtain a white or light yellow solid, i.e., a new crystalline form of tefluthrin.
CO-CRYSTALS
Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.
SWELL1-LRRC8 COMPLEX MODULATORS
The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.
SWELL1-LRRC8 COMPLEX MODULATORS
The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.
Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids
The invention includes procedures for stereoselective β-acylation of carboxylic acids having a β-carbon atom. For example, stereoselective acylation procedures include the following reactions: (I) ##STR00001##
Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids
The invention includes procedures for stereoselective β-acylation of carboxylic acids having a β-carbon atom. For example, stereoselective acylation procedures include the following reactions: (I) ##STR00001##
PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS
The invention includes procedures for stereoselective -acylation of carboxylic acids having a -carbon atom. For example, stereoselective acylation procedures include the following reactions: (I)
##STR00001##
PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS
The invention includes procedures for stereoselective -acylation of carboxylic acids having a -carbon atom. For example, stereoselective acylation procedures include the following reactions: (I)
##STR00001##
Sphingosine kinase inhibitors
The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
Sphingosine kinase inhibitors
The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.